IXICO plc Investor Presentation
13 Agosto 2020 - 1:00AM
RNS Non-Regulatory
TIDMIXI
IXICO plc
13 August 2020
IXICO plc
("IXICO" or the "Company")
Investor Presentation
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that it will provide a live
presentation presented by CEO, Giulio Cerroni and CFO, Grant Nash,
on Tuesday 25 August at 1.30pm.
The Company is committed to providing an opportunity for all
existing and potential investors to hear directly from management,
providing an update on the business and current trading. The
presentation will be hosted through the digital platform Investor
Meet Company. Investors can sign up to Investor Meet Company for
free and add to meet IXICO plc via the following link:
https://www.investormeetcompany.com/ixico-plc/register-investor
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards. No
new price sensitive information will be disclosed, and a PDF of the
presentation will be uploaded to the Company's website.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: 020 7933 8780 or IXICO@walbrookpr.com
Paul McManus / Lianne Cawthorne / Mob: 07980 541 893 / 07584 391 303
Alice Woodings / 07407 804 654
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of AI in
clinical development, to improve biopharma R&D productivity
through the adoption of breakthrough data analytics in precision
healthcare. Through the deployment of novel AI algorithms, we
analyse and interpret brain scans and digital biosensor data to
enable better trial design, patient selection and ultimately
clinical outcomes across all phases of clinical evaluation. Our
data analytics services are deployed on some of the most important
clinical trials in neuroscience, providing valuable insights to
disease progression and patient safety, enabling our clients to
make better informed decisions earlier in the clinical development
pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUURWRRWUWAAR
(END) Dow Jones Newswires
August 13, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024